A phase 1 trial published in Nature Medicine on July 21, 2026, combining englumafusp alfa, a CD19-targeting 4-1BBL co-stimulatory molecule, with glofitamab (Columvi), which Genentech earned accelerated FDA approval for in June 2023, is producing efficacy and safety data that sponsors running bispecific combination studies cannot afford to ignore. The signal buried in trial BP41072 is not the response rate alone. It is the mechanistic architecture underneath it.
For years, the conventional assumption in bispecific antibody development was that adding a second agent to a T-cell engager meant multiplying toxicity risk proportionally. Stack a CD20×CD3 bispecific on top of another immunologically active agent, and you brace for cytokine release syndrome (CRS) that overwhelms any efficacy signal. The BP41072 dataset challenges that calculus directly: the combination’s safety profile remained consistent with glofitamab monotherapy, even as the addition of englumafusp alfa introduced co-stimulatory pressure through the 4-1BB pathway. That is not what the field expected.
A Mechanism That Changes the Dosing Conversation
Understanding why this matters operationally requires a brief step back into the biology. Glofitamab engages CD20 on malignant B cells and CD3 on T cells, physically forcing the immune synapse. But T-cell activation without co-stimulation is notoriously unstable: it can produce exhaustion, anergy, or transient cytolysis rather than durable tumor clearance. Englumafusp alfa addresses this directly by delivering 4-1BBL co-stimulation specifically to the CD19-positive tumor microenvironment, meaning the co-stimulatory signal is concentrated where the T-cell engagement is already happening. The spatial logic is elegant. The trial result is that T-cell amplification did not come at the cost of systemic inflammatory runaway.
For sponsors designing combination bispecific studies, that mechanistic specificity has concrete protocol implications. Obinutuzumab pretreatment was used in BP41072 to deplete circulating B cells before the combination was introduced, a step designed to reduce the peripheral antigen burden that drives first-dose CRS events. Sponsors who have run glofitamab monotherapy trials know this pretreatment step well; what BP41072 tests is whether that mitigation strategy scales when a second immunologically active agent enters the picture. The answer, at least at phase 1 dose levels, appears to be yes.
Compare this to what odronextamab (REGN1979), another CD20×CD3 bispecific, produced in its own phase 1 expansion study: among 127 heavily pretreated relapsed/refractory B-NHL patients, the drug showed encouraging single-agent activity with an acceptable safety profile, but that was monotherapy. The BP41072 data now asks whether rational co-stimulatory layering can push response depth further without cracking the safety envelope that monotherapy established.
Who Runs These Trials Differently Starting Now
The therapeutic areas most immediately affected are diffuse large B-cell lymphomaB-cell lymphoma and the broader relapsed/refractory B-NHL space, where glofitamab already holds an accelerated approval label. Sponsors running phase 2 combination studies that build on that monotherapy backbone should be revisiting their dose-escalation schemas and CRS management algorithms in light of BP41072’s pretreatment and step-up dosing architecture. The trial’s safety data directly informs what a defensible starting dose looks like when 4-1BB co-stimulation is layered in.
Patient recruitment strategy also shifts. BP41072 enrolled patients with relapsed or refractory B-NHL, a population that has frequently exhausted CD20-directed chemoimmunotherapy and may have prior CAR-T exposure. That eligibility profile is becoming standard in bispecific trials, but it creates a selection pressure that complicates efficacy interpretation: responders in this population are, by definition, exceptional. Sponsors planning registrational follow-on studies will need to think carefully about whether their phase 2 eligibility criteria should be broader or narrower than what BP41072 used, and how prior bispecific or CAR-T exposure will be handled as an exclusion criterion.
The publication venue matters here too. Nature Medicine accepts fewer than 8% of submissions and desk-rejects roughly 70-85% before peer review, according to Manusights’ submission analysis. Phase 1 oncology data clears that bar only when the translational bridge, the line connecting mechanistic rationale to clinical signal, is strong enough to stand alone. The fact that BP41072 cleared it tells you something about how reviewers assessed the biological coherence of the englumafusp alfa mechanism. Sponsors should read the supplementary data with that standard in mind.
What Clinical Operations Leaders Should Do This Week
If you are running a bispecific combination study in aggressive B-cell lymphoma with a CD3-engaging backbone, pull BP41072’s step-up dosing schedule and pretreatment protocol now. The obinutuzumab pretreatment timing and the englumafusp alfa escalation schema represent the current leading edge of how to manage co-stimulatory combinations without triggering unmanageable CRS. Your Data Safety Monitoring Board charter and dose-limiting toxicity definitions should be reviewed against this dataset before your next interim analysis. Protocol amendment requests based on emerging combination safety data have a documented habit of arriving just before enrollment milestones, and regulators expect sponsors to cite contemporaneous phase 1 evidence when they do.
The next signal to watch arrives from the phase 2 design decisions that Genentech and partner sponsors make in the second half of 2026. Glofitamab’s accelerated approval in DLBCL requires a confirmatory trial; the question is whether that confirmatory program will incorporate the englumafusp alfa combination or run glofitamab monotherapy forward as the confirmatory anchor. The answer will tell you whether the BP41072 mechanism is being treated as a registrational asset or a biomarker exploration exercise. Watch the IND amendments and any Type B meeting disclosures that surface before year-end. That is where the regulatory posture on co-stimulatory bispecific combinations will be written in real time.
References
- Nature Medicine — “Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial”
- FDA — “FDA Grants Accelerated Approval: Glofitamab-gxbm (Columvi), June 15, 2023”
- CancerNetwork — “Englumafusp Alfa Combo Shows Encouraging Activity in B-Cell Lymphoma (BP41072, NCT04077723)”
- ASH Publications — “Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Phase 1 Study (NCT02290951)”
- Manusights — “Nature Medicine Submission Guide: Acceptance Rate and Peer Review Standards”
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
